Back to homepage

Tag "relapse"

Corrigendum: Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

Authors: George J Wan PhD, Ishveen Chopra PhD, John Niewoehner PharmD, Samuel F Hunter MD, PhD

Wan GJ, Chopra I, Niewoehner J, Hunter SF. Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis. Drugs in Context 2020; 9: 2020-9-4. DOI: 10.7573/dic.2020-9-4

More

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

Authors: George J Wan PhD, Ishveen Chopra PhD, John Niewoehner PharmD, Samuel F Hunter MD, PhD

The objective of this study was to estimate the cost per response of repository corticotropin injection compared with plasmapheresis or intravenous immunoglobulin from the United States commercial payer perspective.

More

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Authors: Michele Wilson, Benjamin Gutierrez, Steve J Offord, Christopher M Blanchette, Anna Eramo, Stephanie Earnshaw, Siddhesh A Kamat

Schizophrenia is associated with high direct healthcare costs due to progression of disease and frequent occurrence of relapses. Aripiprazole once-monthly (AOM) has been shown to reduce total psychiatric hospitalizations among patients who switched from oral standard of care (SOC) therapy to AOM. In this paper the authors report the results of an economic model study to evaluate the psychiatric hospitalization-related medical costs and antipsychotic pharmacy costs during a 6-month period before and after initiation of AOM treatment.

More